Literature DB >> 8770301

Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases.

S Schneebaum1, M W Arnold, A Staubus, D C Young, D Dumond, E W Martin.   

Abstract

BACKGROUND: Intraperitoneal (i.p.) metastases pose a special problem for surgical treatment because of their multiplicity and microscopic size. This study was designed to examine the feasibility and safety of i.p. hyperthermic perfusion (IPHP) with mitomycin C (MMC) for treating recurrent colorectal cancer.
METHODS: Fifteen patients with metastatic colon cancer were treated. All patients underwent cytoreductive procedures leaving only residual i.p. metastases < 1 cm in diameter. All patients had received prior systemic chemotherapy, but their disease had progressed. Intraperitoneal chemotherapy was administered through three large catheters (28 French) using a closed system of two pumps, a heat exchanger, and two filters. After the patient's abdominal temperature reached 41 degrees C, 45-60 mg of MMC was circulated intraperitoneally for 1 h.
RESULTS: The majority of patients had various anastomoses: small bowel (n = 11), large bowel (n = 5), and urologic (n = 5). No anastomotic complications occurred in any of the patients. One patient experienced severe systemic MMC toxicity, which caused cytopenia and respiratory depression. In all patients the carcinoembryonic antigen (CEA) level decreased after surgery and IPHP. Median follow-up was 10 months, and recurrence was defined as an elevation in CEA level. Disease recurred in three patients within 5 months, and disease recurred in seven other patients over the next 3 months; one patient remains clinically free of disease after 8 months.
CONCLUSION: Our data suggest that IPHP is a safe palliative method of treatment for patients with peritoneal carcinomatosis. The median patient response duration of 6 months may warrant consideration of a repeat IPHP procedure at that time.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770301     DOI: 10.1007/bf02409050

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies.

Authors:  P H Sugarbaker; T Graves; E A DeBruijn; W J Cunliffe; R E Mullins; W E Hull; L Oliff; P Schlag
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

2.  Areas of failure found at reoperation (second or symptomatic look) following "curative surgery" for adenocarcinoma of the rectum. Clinicopathologic correlation and implications for adjuvant therapy.

Authors:  L L Gunderson; H Sosin
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

3.  Selective heat sensitivity of cancer cells. Biochemical and clinical studies.

Authors:  R Cavaliere; E C Ciocatto; B C Giovanella; C Heidelberger; R O Johnson; M Margottini; B Mondovi; G Moricca; A Rossi-Fanelli
Journal:  Cancer       Date:  1967-09       Impact factor: 6.860

Review 4.  Intraperitoneal chemotherapy: a review.

Authors:  D E Brenner
Journal:  J Clin Oncol       Date:  1986-07       Impact factor: 44.544

5.  Intraperitoneal approach to regional hyperthermia--possible anticancer applications.

Authors:  G V Smith; R MacMillan; J Stribling
Journal:  World J Surg       Date:  1983-11       Impact factor: 3.352

6.  Influence of perioperative cis-platinum on breaking strength of bowel anastomoses in rats.

Authors:  U Engelmann; W Sonntag; G H Jacobi
Journal:  Recent Results Cancer Res       Date:  1985

7.  Surgical considerations in ovarian cancer.

Authors:  C J Cohen
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

8.  Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding.

Authors:  S Fujimoto; R D Shrestha; M Kokubun; M Ohta; M Takahashi; K Kobayashi; S Kiuchi; K Okui; T Miyoshi; N Arimizu
Journal:  Ann Surg       Date:  1988-07       Impact factor: 12.969

9.  Clinical delivery system for intraperitoneal hyperthermic chemotherapy.

Authors:  J S Spratt; R A Adcock; M Muskovin; W Sherrill; J McKeown
Journal:  Cancer Res       Date:  1980-02       Impact factor: 12.701

10.  Prevention of scald injury on the peritoneo-serosal surface in advanced gastric cancer patients treated with intraperitoneal hyperthermic perfusion.

Authors:  S Fujimoto; M Kokubun; R D Shrestha; K Kobayashi; S Kiuchi; C Konno; M Takahashi; K Okui
Journal:  Int J Hyperthermia       Date:  1991 Jul-Aug       Impact factor: 3.914

View more
  12 in total

1.  Colorectal Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

2.  Peritoneal carcinomatosis of colorectal origin: standard of care.

Authors:  Tristan D Yan
Journal:  Ann Surg       Date:  2006-10       Impact factor: 12.969

Review 3.  Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.

Authors:  Manuel J Koppe; Otto C Boerman; Wim J G Oyen; Robert P Bleichrodt
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

Review 4.  Management of peritoneal carcinomatosis from colorectal cancer: review of the literature.

Authors:  Carlo Vallicelli; Davide Cavaliere; Fausto Catena; Federico Coccolini; Luca Ansaloni; Elia Poiasina; Hariscine K Abongwa; Belinda De Simone; Laura Alberici; Massimo Framarini; Giorgio M Verdecchia
Journal:  Int J Colorectal Dis       Date:  2014-06-11       Impact factor: 2.571

5.  HIPEC Methodology and Regimens: The Need for an Expert Consensus.

Authors:  Aditi Bhatt; Ignace de Hingh; Kurt Van Der Speeten; Martin Hubner; Marcello Deraco; Naoual Bakrin; Laurent Villeneuve; Shigeki Kusamura; Olivier Glehen
Journal:  Ann Surg Oncol       Date:  2021-06-17       Impact factor: 5.344

6.  Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer.

Authors:  Claudio Zanon; Massimiliano Bortolini; Isabella Chiappino; Paolo Simone; Francesco Bruno; Piero Gaglia; Mario Airoldi; Leonorda Deriu; Alon Mashiah
Journal:  World J Surg       Date:  2006-11       Impact factor: 3.352

Review 7.  Treatment recommendations for metastatic colorectal cancer.

Authors:  Enrique Aranda; Albert Abad; Alfredo Carrato; Andrés Cervantes; Jesús García-Foncillas; Pilar García Alfonso; Rocío García Carbonero; Auxiliadora Gómez España; Josep M Tabernero; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

Review 8.  Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future.

Authors:  Ahmed Dehal; J Joshua Smith; Garrett M Nash
Journal:  J Gastrointest Oncol       Date:  2016-02

9.  Biodegradable intraprostatic doxorubicin implants.

Authors:  Ronnie Ortiz; Jessie L-S Au; Ze Lu; Yuebo Gan; M Guillaume Wientjes
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

10.  Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options.

Authors:  Yvonne L B Klaver; Valery E P P Lemmens; Simon W Nienhuijs; Misha D P Luyer; Ignace H J T de Hingh
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.